Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170.
Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, Fogliatto L, Garcia-Sancho AM, Christian B, Gulbas Z, Özcan M, Perini GF, Ghesquieres H, Shipp MA, Thompson S, Chakraborty S, Marinello P, Armand P. Zinzani PL, et al. Among authors: perini gf. Blood. 2023 Jul 13;142(2):141-145. doi: 10.1182/blood.2022019340. Blood. 2023. PMID: 37130017 Free PMC article. Clinical Trial.
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Fogliatto LM, Goncalves I, de Oliveira JSR, Buccheri V, Perini GF, Goldschmidt N, Kriachok I, Dickinson M, Komarnicki M, McDonald A, Ozcan M, Sekiguchi N, Zhu Y, Nahar A, Marinello P, Zinzani PL; KEYNOTE-204 investigators. Kuruvilla J, et al. Among authors: perini gf. Lancet Oncol. 2021 Apr;22(4):512-524. doi: 10.1016/S1470-2045(21)00005-X. Epub 2021 Mar 12. Lancet Oncol. 2021. PMID: 33721562 Clinical Trial.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Wang ML, et al. Among authors: perini gf. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. N Engl J Med. 2022. PMID: 35657079 Clinical Trial.
Fine and Gray or Cox model?
Arcuri LJ, Souza Santos FP, Perini GF, Hamerschlak N. Arcuri LJ, et al. Among authors: perini gf. Blood Adv. 2024 Mar 26;8(6):1420-1421. doi: 10.1182/bloodadvances.2023012157. Blood Adv. 2024. PMID: 38191679 Free PMC article. No abstract available.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs R, Ahn IE, Pu J, Isaac KM, Barr PM, Ujjani CS, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR, Koropsak M, Bailey N, Hanson L, Perini GF, Ma S, Ryan CE, Wiestner A, Portell CA, Shadman M, Chong EA, Brander DM, Sundaram S, Seddon AN, Seymour E, Patel M, Martinez-Calle N, Munir T, Walewska R, Broom A, Walter H, El-Sharkawi D, Parry H, Wilson MR, Patten PEM, Hernández-Rivas JÁ, Miras F, Fernández Escalada N, Ghione P, Nabhan C, Lebowitz S, Bhavsar E, López-Jiménez J, Naya D, Garcia-Marco JA, Skånland SS, Cordoba R, Eyre TA. Mato AR, et al. Among authors: perini gf. Blood. 2020 Sep 3;136(10):1134-1143. doi: 10.1182/blood.2020006965. Blood. 2020. PMID: 32688395 Free PMC article. Clinical Trial.
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Roeker LE, Eyre TA, Thompson MC, Lamanna N, Coltoff AR, Davids MS, Baker PO, Leslie L, Rogers KA, Allan JN, Cordoba R, Lopez-Garcia A, Antic D, Pagel JM, Martinez-Calle N, García-Marco JA, Hernández-Rivas JÁ, Miras F, Coombs CC, Österborg A, Hansson L, Seddon AN, López Jiménez J, Wilson MR, El-Sharkawi D, Wojenski D, Ma S, Munir T, Valenciano S, Seymour E, Barr PM, Pu J, Patten PEM, Perini GF, Huntington SF, Parry H, Sundaram S, Skarbnik A, Kamdar M, Jacobs R, Walter H, Walewska R, Broom A, Lebowitz S, Isaac KM, Portell CA, Ahn IE, Ujjani CS, Shadman M, Skånland SS, Chong EA, Mato AR. Roeker LE, et al. Among authors: perini gf. Blood. 2021 Nov 4;138(18):1768-1773. doi: 10.1182/blood.2021011841. Blood. 2021. PMID: 34297826 Free PMC article. No abstract available.
Editorial: Advances in the treatment of Hodgkin lymphoma.
Mei M, Perini G, Ramchandren R. Mei M, et al. Front Oncol. 2023 Feb 28;13:1164081. doi: 10.3389/fonc.2023.1164081. eCollection 2023. Front Oncol. 2023. PMID: 36925934 Free PMC article. No abstract available.
Brentuximab Vedotin in CD30+ Lymphomas.
Perini GF, Pro B. Perini GF, et al. Biol Ther. 2013;3(1):15-23. doi: 10.1007/s13554-013-0008-7. Epub 2013 Mar 1. Biol Ther. 2013. PMID: 24392301 Free PMC article. Review.
37 results